PD-L1 expression in tongue squamous cell carcinoma.
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ analysis
Chemotherapy, Adjuvant
/ methods
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
/ immunology
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunohistochemistry
Male
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Prognosis
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnosis
Tongue
/ pathology
Tongue Neoplasms
/ diagnosis
Up-Regulation
/ immunology
Young Adult
Adjuvant therapy
Nodal metastasis
Programmed cell death 1
Programmed cell death 1 ligand
Tongue squamous cell carcinoma
Journal
Medical molecular morphology
ISSN: 1860-1499
Titre abrégé: Med Mol Morphol
Pays: Japan
ID NLM: 101239023
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
16
05
2020
accepted:
13
07
2020
pubmed:
24
7
2020
medline:
3
11
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
Immune checkpoint proteins programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are important therapeutic targets for head and neck cancer. This large-scale case study aimed to analyze tongue squamous cell carcinomas (SCCs) and evaluate the correlation between PD-L1 expression and clinical prognosis. So far, this study is the largest case study on PD-L1 expression in tongue SCCs. This is a case-control study that analyzed 121 tongue SCCs. Paraffin-embedded sections and clinical data were obtained retrospectively and immunohistochemistry with PD-L1 was performed. 11.6% contained ≥ 50% of PD-L1-positive cells, 57.1% of these cases had a poor prognosis with nodal metastasis. Among cases of T1/2 primary lesions with nodal metastasis, cases of high PD-L1 expression had a significantly shorter disease-free survival than cases of no PD-L1 expression (p = 0.018). The hazard ratio for high PD-L1 expression was 3.21 (95 per cent CI, 1.26-8.72) compared with no PD-L1 expression after adjusting for other factors. These data indicate that PD-L1 upregulation in tongue SCCs is associated with a more advanced stage and shorter disease-free survival. PD-1/PD-L1 inhibitors might hence constitute potential adjuvant therapy for tongue SCCs with PD-L1 upregulation.
Identifiants
pubmed: 32699939
doi: 10.1007/s00795-020-00261-7
pii: 10.1007/s00795-020-00261-7
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-59Commentaires et corrections
Type : ErratumIn
Références
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
doi: 10.1002/ijc.29210
Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, Hicks WL, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A, Urba S, Weymuller EA, Wheeler RH, Wolf GT (2000) NCCN practice guidelines for head and neck cancers. Oncology 14:163–194
pubmed: 11195409
Guidi A, Codecà C, Ferrari D (2018) Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol 35:37
doi: 10.1007/s12032-018-1096-5
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
doi: 10.1056/NEJMoa0802656
Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen C-J, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M (2017) A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol 73:138–146
doi: 10.1016/j.oraloncology.2017.07.023
Scognamiglio T, Chen Y-T (2018) Beyond the percentages of PD-L1-positive tumor cells: induced versus constitutive PD-L1 expression in primary and metastatic head and neck squamous cell carcinoma. Head Neck Pathol 12:221–229
doi: 10.1007/s12105-017-0857-3
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867
doi: 10.1056/NEJMoa1602252
O’Sullivan B (2010) International Union Against Cancer (UICC). Lip and oral cavity. In: Sobin LH, Gospo- darowicz MK, Wittekind C (eds) TNM classification of malignant tumours. 7th ed. New York: Wiley; 2010. p. 25–29
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM (2017) PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 12:208–222
doi: 10.1016/j.jtho.2016.11.2228
Chen SC, Chang PMH, Wang HJ, Tai SK, Chu PY, Yang MH (2018) PD-L1 expression is associated with p16INK4Aexpression in non-oropharyngeal head and neck squamous cell carcinoma. Oncol Lett 15:2259–2265
pubmed: 29434933
Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G (2018) PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology 73:573–584
doi: 10.1111/his.13646
Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, Boyer M, Scolyer RA, Clark JR (2016) Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology 48:574–580
doi: 10.1016/j.pathol.2016.07.003
Maruse Y, Kawano S, Jinno T, Matsubara R, Goto Y, Kaneko N, Sakamoto T, Hashiguchi Y, Moriyama M, Toyoshima T, Kitamura R, Tanaka H, Oobu K, Kiyoshima T, Nakamura S (2018) Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 47:836–845
doi: 10.1016/j.ijom.2018.01.004
Straub M, Drecoll E, Pfarr N, Weichert W, Langer R, Hapfelmeier A, Götz C, Wolff KD, Kolk A, Specht K (2016) CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget Impact J 7:12024–12034
doi: 10.18632/oncotarget.7593
Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Schu X, Cheng JD, Haddad R (2017) Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol 35:1542–1549
doi: 10.1200/JCO.2016.70.1524
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
doi: 10.1056/NEJMoa1501824
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim J, Arvis CD, Ahn M, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, ShentuY IME, Dolled Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550
doi: 10.1016/S0140-6736(15)01281-7
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833
doi: 10.1056/NEJMoa1606774
Haratake N, Toyokawa G, Tagawa T, Kozuma Y, Matsubara T, Takamori S, Akamine T, Yamada Y, Oda Y, Maehara Y (2017) Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. Anticancer Res 37:5713–5717
pubmed: 28982891
Lin Y, Sung W, Hsieh M, Tsai S, Lai H, Yang S, Chen K, Chen M, Lee H, Yeh K, Chen C (2015) High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. Suzuki H, editor. PLoS ONE 10:e0142656
Hanna GJ, Woo SB, Li YY, Barletta JA, Hammerman PS, Lorch JH (2018) Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Oral Maxillofacial Surg 47:568–577